aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International Conference
“We are excited to present a thorough summary of our preclinical work from our ATYR1923 program, specifically as it relates to potential activity in interstitial lung diseases at the
Title: “Preclinical Characterization of ATYR1923 (iMod.Fc), an Immune-Modulatory Therapeutic with Potentially Broad Application in Interstitial Lung Diseases”
- ATYR1923 has been engineered to have a long duration of action and is efficacious in bleomycin-induced lung fibrosis preclinical models when administered weekly.
- Data demonstrates that ATYR1923 dosing results in improved lung function and reduced inflammation after bleomycin induced lung injury in rats.
- Pharmacokinetic data in rats and nonhuman primates predict once monthly dosing in patients.
- Favorable safety profile observed from one- and three-month GLP toxicity studies in rats and nonhuman primates at weekly doses up to 60mg/kg with no observed adverse effects.
- Based on the preclinical data, a Phase 1 first–in-human clinical study was initiated.
aTyr is a clinical-stage biotechnology company engaged in the discovery and clinical development of innovative medicines using its knowledge of tRNA synthetase biology. The company is focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase (HARS) gene family. aTyr’s clinical stage ATYR1923 candidate augments the Resokine pathway and is designed to temper immune engagement in interstitial lung diseases. aTyr’s immuno-oncology research program, targets the Resokine pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 250 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit http://www.atyrpharma.com.
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the potential therapeutic benefits and applications of our product candidates, our ability to successfully advance our pipeline or product candidates, undertake certain development activities (such as
clinical trial enrollment, the conduct of clinical trials and the announcement of top-line results), and accomplish certain development goals, and the timing of such events and the scope and strength of our intellectual property portfolio reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the discovery, development and regulation of our product candidates, the risk that we may cease or delay preclinical or clinical development activities for any of its existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), and the risk that we may not be able to raise the additional funding required for its business and product development plans, as well as those set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other
Sr. Director, Investor Relations
Source: aTyr Pharma, Inc.